Medicine & Pharmacy Blog

eDrugSearch.com, the comparison shopping site for prescription drug consumers, took part in a television panel discussion on the topic of Internet pharmacy safety.

San Antonio, TX (PRWEB) June 7, 2008 — eDrugSearch.com, the popular prescription drug shopping site and social network, continued its mission to educate consumers about Internet pharmacies with an appearance on the nationally syndicated Morning Show with Mike and Juliet on Monday, June 2.

eDrugSearch.com spokesman Scott Baradell communicated some of the benefits of online pharmacies, including convenience and privacy.

Like other panel participants, eDrugSearch.com expressed concern about rogue pharmacies that are selling drugs, including controlled substances, without a doctor's prescription. eDrugSearch.com allows only licensed, accredited pharmacies in its shopping engine — primarily from Canada and the United States.

Watch the panel discussion here: http://www.edrugsearch.com/edsblog/edrugsearchcom-featured-on-the-morning-show-with-mike-and-juliet/

"This is an important step in our efforts to educate the public, which has been given a lot of confusing information about Internet pharmacies," said Cary Byrd, founder and president of eDrugSearch.com.

"The FDA needs to focus more resources on shutting down rogue pharmacies, which are no better than street-corner drug dealers. At the same time, it's important not to tar all Internet pharmacies with the same broad brush."

eDrugSearch.com offers a safe haven for consumers shopping for prescription drugs online. In choosing an Internet pharmacy, the company recommends the pharmacies listed at this url: http://www.edrugsearch.com/pharmacy-directory.

Consumers can register for a free membership with eDrugSearch.com at the following url: http://www.edrugsearch.com/register.

About eDrugSearch.com :
Based in San Antonio, eDrugSearch.com is the Health 2.0 social network and comparison shopping site for U.S. consumers seeking prescription medications from prescreened Canadian and other international pharmacies. eDrugSearch.com's social network empowers members to rate and review pharmacies, share experiences with other members, and more. eDrugSearch.com president and founder Cary Byrd is an impassioned advocate for reform of U.S. prescription-drug law. For more information, visit the company's Web site at www.eDrugSearch.com or its blog at www.edrugsearch.com/edsblog.

See Also:

• Emotional Freedom Technique (EFT): What it is and What You Should Know
• Beauti-ceuticals Nutrition and Skin Care Meet for Healthiest Skin Results
• Effective Ways to Lock in That Essential Moisture
• The Emotional Freedom Technique to Achieve Personal Success
• Can a Child Display Autistic Traits and Still Not Be Autistic?

[Via Pharmaceuticals]

IMULAN has initiated additional clinical trials to assess the effects of the first and only approved treatment aid in the United States for feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV or Feline AIDS).

Prescott, AZ (PRWEB) June 6, 2008 — IMULAN BioTherapeutics (IMULAN) announced they have initiated a multi-site clinical trial to further assess the effect of Lymphocyte T-Cell Immunomodulator (LTCI) in cats with feline leukemia virus, a prevalent retroviral infections in domestic cats. LTCI is the first and only approved treatment aid in the United States for cats infected with feline leukemia virus (FeLV) and immunodeficiency virus (FIV) and the associated symptoms of lymphopenia, opportunistic infection, anemia, granulocytopenia, or thrombocytopenia.

Dr. Craig Woods, CEO of IMULAN, stated, "IMULAN has started the first in a series of studies to examine the effects of LTCI for feline leukemia virus. The first study will further characterize the clinical and immunological effects of this exciting new biologic for feline leukemia virus patients."

Dr. Craig Woods went on to state, "Lymphocyte T-Cell Immune Modulator is a potent regulator of lymphocyte production and function and has been shown to increase lymphocyte numbers and interleukin-2 production in animals. Lymphocytes and interleukin-2 play a pivotal role in eliciting an immune response against viruses. IMULAN believes this immunological approach will be far more effective than metabolic drug approaches, none of which are approved for feline viral infections."

About Feline Leukemia Virus (FeLV): Feline leukemia virus, a retrovirus, is an infectious disease of cats that often results in immune dysfunction and can be associated with certain forms of feline cancer, including leukemia and lymphoma. All retroviruses, including FeLV, feline immunodeficiency virus (FIV) and human immunodeficiency virus (HIV), produce an enzyme, reverse transcriptase, which permits them to insert copies of their own genetic material into host cells.

About Lymphocyte T-Cell Immunomodulator: LTCI is a conditionally approved treatment aid for cats infected with Feline Leukemia Virus (FeLV) and/or Feline Immunodeficiency Virus (FIV). Conditional licenses are granted by the United States Department of Agriculture Center for Veterinary Biologics to products that have met reasonable expectation of efficacy, have demonstrated purity, and passed safety testing. LTCI is manufactured by T-Cyte Therapeutics, Inc. and is exclusively distributed by IMULAN BioTherapeutics.

About IMULAN: IMULAN develops unique, precision immune regulating compounds for veterinary medicine. IMULAN's primary focus is on biological strategies that combine peptide pharmacology with immunology to treat infectious, autoimmune, and immune mediated diseases in small and large animal medicine. IMULAN recently commercialized Lymphocyte T-Cell Immunomodulator as a conditionally licensed treatment aid for cats infected with feline leukemia and immunodeficiency virus. For more information about IMULAN, please visit www.imulan.com

See Also:

• CDC Study: Junk Food in Utah Schools a “Killer at Large”
• Successful Achievement Coach Dax Moy Shares The Secrets To His
• An Overview on All-Natural Wrinkle Creams
• Different Types of Panic Attacks Exposed
• CDC Study: Junk Food in Utah Schools a “Killer at Large”

[Via Pharmaceuticals]

America Hears, Inc., announced an agreement to equip its entire family of premium digital hearing aids with sophisticated sound-processing software from Dynamic Hearing Pty Ltd. of Australia. Standardizing on Dynamic Hearing's robust software platform will enable America Hears to continue expanding the global hearing-aid market by delivering the most advanced hearing aids direct to consumers and supporting them over the internet with a flexible choice of programmable solutions.

Bristol, PA (PRWEB) June 6, 2008 –America Hears, Inc., today announced an agreement to equip its entire family of premium digital hearing aids with sophisticated sound-processing software from Dynamic Hearing Pty Ltd of Australia. According to America Hears CEO Henry C. Smith, naming Dynamic Hearing its Supplier of Choice and standardizing on the company's robust software platform will enable America Hears to continue expanding the global hearing-aid market by delivering the most advanced hearing aids direct to consumers and supporting them over the internet with a flexible choice of programmable solutions.

Dynamic Hearing is a closely held Australian technology company that develops and licenses advanced digital signal processing (DSP) algorithms and software to international manufacturers of personal communication devices, including hearing aids and headsets. Its ADRO® (Advanced Dynamic Range Optimization) amplification technology is the most sophisticated software available for digital hearing aids. The ADRO® Digital Sound Processing platform's real-time statistical analysis and automatic-adjustment capabilities enable hearing-aid designers to optimize the listening experience with products that continuously adapt to the changing acoustical environment as well as to users' specific personal hearing profiles.

According to Elaine Saunders, PhD, CEO of Dynamic Hearing, the agreement is the culmination of a long-term relationship in which America Hears has provided invaluable customer feedback and design experience for new versions of the ADRO platform. "Dynamic Hearing is focused on real-world solutions to people's hearing problems," Saunders said. "Our partnership with America Hears has enabled us to stay at the forefront of the hearing-aid industry with software that unleashes the digital power of each successive generation of new DSP chips."

Dynamic Hearing's ADRO algorithm, developed for the current and future generations of powerful digital signal processing chips, provides performance superior to the compression technologies used in many of today's hearing aids. In trials conducted by the Cooperative Research Centre for Cochlear Implant and Hearing Aid Innovation, hearing-aid users preferred ADRO over compression technologies 74% of the time.

America Hears is the world's only manufacturer of premium digital hearing aids to sell and support its products directly over the internet. By making appropriately priced hearing-assistance products easily available to a broader market than ever before, America Hears is helping to expand the hearing-aid industry, which has experienced disappointingly slow growth in spite of the rapidly growing population of Baby Boomers suffering from age-related hearing loss.

The combination of America Hears' design and manufacturing experience with Dynamic Hearing's ADRO software running on the latest generation of DSP chips promises to deliver hearing-assistance products with more capabilities at more appropriate prices than ever before. Smith said the companies' shared vision is to finally put hearing aids within the reach of the mass market for consumer electronics. "Anyone who can afford an IPod and a new mobile phone should be able to get the digital hearing assistance they require as well," Smith said. "Now, with America Hears products integrating ADRO software from Dynamic Hearing, they can."

See Also:

• Break Out Of Age!
• Adolph Kiefer & Associates Sponsor Sweepstakes to U.S. Olympic Swimming Trials in Nebraska
• Boost Vitality And Energy With Deer Antler Velvet
• The Natural Skin Care Product Revolution
• CDC Study: Junk Food in Utah Schools a “Killer at Large”

[Via Family Medicine]

It has taken a very long time for a major new gout drug to be developed and approved. Probably the best gout news in over 40 years, is that Febuxostat, which has been given the trade/brand name of Adenuric, has been approved by the European Medicines Agency for marketing in European Union (EU) countries.

This approval applies only to EU countries. Febuxostat has not yet been approved in the United States. If you are reading this from a non-EU country, or the US, you can check with your doctor to find out whether, or when, Febuxostat will be approved in your country.

Approval in one country does not mean approval in another, but the fact that the European Medicines Agency has approved it will carry weight when the medical authorities in other countries consider its approval.

BENEFITS

In large trials Febuxostat (Adenuric) has outperformed Allopurinol, the most common gout medication for long term treatment. Like Allopurinol, it works to lower uric acid production by inhibiting xanthine oxidase, an enzyme required to produce uric acid. In two major studies it reduced uric acid (UA) in more gout sufferers, and more patients reached the target 6.0 mg/dL level more quickly, than did those on Allopurinol.

At 120 mg it has reduced UA levels to the target of 6.0 mg/dL in over 60% of study patients. At 80 mg the numbers were around 51%. Allopurinol at a 300 mg dosage in most participants achieved this is 22% of study patients. Hence the excited buzz in rheumatology circles since these kinds of results became apparent in its trials. At or below 6.0 mg/dL gout is more likely to be cured or managed better.

Generally, Febuxostat has been more effective when UA levels are below 10.0 mg/dL (595 mmol/µmol). However, even if they have been above this level, it has reduced UA levels down to the target in about 40% of study patients at an 80 mg dosage, and by more at higher dosages.

IT’S NOT PERFECT

In trials its success rate in reducing UA levels down to the important 6.0 mg/dL (357 mmol/µmol) level was not 100%. About 35% of trial patients did not achieve the target. This may have been partly because so many gout sufferers are not UA over-producers, the problem Febuxostat addresses, but under-excretors of uric acid.

And it may cause side effects of course. See the bottom of this article.

Febuxostat (Adenuric) is not unfortunately a treatment for gout pain. It won’t be used instead of NSAIDS like Indomethacin, Colchicine, and corticosteroids.

It is recommended that NSAIDs or Colchicine are used along with Adenuric. This is because, as with Allopurinol, on a course of Febuxostat, there may be an initial increase in gout flares. If this happens you must battle through the attacks and continue taking Adenuric.

It will also only be used in gout patients who have chronic hyperuricemia (high UA levels) and gout.

So if you’re a gout sufferer who lives in a European country that’s a member of the EU, you can ask your doctor’s opinion about whether Febuxostat is suitable for you.

WHO WILL BE PRESCRIBED IT?

The recommended dose is one 80 mg daily tablet. If after two weeks there is no reduction in UA levels, your doctor may increase the dose to 120 mg daily. Patients will need another serum UA test after two weeks treatment to find out how well it’s doing. In trials it has usually worked quickly, within a couple of weeks.

Your uric acid levels will have to be high. If you have gout but normal or slightly raised uric acid levels as some do, it is unlikely to be prescribed.

Tophi If you have tophi, it’s heartening to know that Febuxostat has been shown to have success against tophi. Measured tophi areas reduced in many patients with tophi. The presence of tophi will be an additional factor in favour of a decision to prescribe Febuxostat (Adenuric).

You will not need to be on a low purine diet, and more good news is that it can be prescribed for the elderly.

Kidney and liver disease In trials it has performed quite well with patients who have mild kidney disease. 44% of patients achieved the target at an 80 mg dosage, more at higher dosages. Better results than Allopurinol. If you have mild kidney disease (renal impairment) or mild liver problems (hepatic impairment) your doctor will judge whether Adenuric/Febuxostat can be taken safely.

If you have severe kidney or liver problems Febuxostat is not recommended since it has not been tested in these patient groups. It is not recommended for people with heart disease or children.

Noted possible side effects dizziness, drowsiness, diarrhoea, rashes, headaches, hypertension and liver function abnormalities – considered mild ones. In trials none of these side effects were reported in more than 3.5% of trial patients. The most common were liver function abnormalities.

NB. The contents of this article contain medical information not medical advice. Please always discuss remedies with your doctor or other health care professional, before implementing any treatment.

See Also:

• Mueller’s(R) Pasta Partners With American Diabetes Association for The ‘Tour De Cure’
• Basic Medical Knowledge and Specialties
• Recurring Yeast Infections and Alcoholic Beverages
• Abbott Declares 338th Consecutive Quarterly Dividend
• Highmark Inc. Moves Forward With Funding for Physician Adoption of Health Information Technology

[Via Medicine]

Lenore Howe, CEO and President of Care Seeker, LLC, a member company of the Wellness Partners Group, announced the release today of a new feature that allows more people to search the SEPHIA™ Database of pelvic health professionals.

Concord, NH (PRWEB) June 5, 2008 — Lenore Howe, CEO and President of Care Seeker, LLC, a member company of the Wellness Partners Group, announced the release today of a new feature that allows more people to search the SEPHIA™ Database of pelvic health professionals. Created a year ago, SEPHIA™ (Search Engine for Pelvic Health Information and Associates) is designed to help both patients and health care professionals find qualified pelvic health specialists. The service, which requires a simple registration, is available for unlimited searches at www.SEPHIAsChoice.com. A new widget, available at http://www.sephiaschoice.com/sephiawidget, allows website owners and managers to offer SEPHIA™ Search to their own visitors. Webmasters, editors and managers of health, caregiver or senior oriented websites are urged to take advantage of this free service.

SEPHIA™ has been well-received by the public but the website owners want to help even more people to access the listings in the Database. "SEPHIA™ is an excellent public service and should be available on every website where people with pelvic health issues are seeking help", says Howe. "Now, anyone who owns or manages a website can copy and paste the widget code into a page on their website and make the Database of health professionals available to his or her website visitors at no cost."

SEPHIA™ is a database of pelvic health specialists with detailed information about their practices including the specific services they provide, conditions they treat, setting, type of practice and patient target group. The Database is searchable by geographic area and condition. An advanced feature gives site visitors the ability to find very specific services with up to fifteen search variables.

The goal of SEPHIA™ is to help consumers find specific continence services and to assist health professionals in referring their patients to qualified service providers. This highly specialized group, continence service providers, is scattered among a variety of settings including gynecology and urology practices. Until now, there has been no easy way for their services to be made readily available to the public. Searches in SEPHIATM are currently free as are listings for qualified pelvic health professionals.

Diane K. Newman, RNC MSN, CRNP FAAN, a certified nurse practitioner and an international expert in the area of pelvic floor dysfunction has been working for years to create a network of highly specialized continence nurses and other pelvic health specialists. SEPHIAsChoice.com has become an important source of new patients for this group as well as a basis for networking with peers in their local geographic areas.

If you are a currently licensed medical professional that provides continence services as listed below, you are eligible for a listing in SEPHIA™. Visit http://www.sephiaschoice.com/register/ and enter your information.

Continence services include:

• Assessment of pelvic floor, anal manometry, urodynamics, videourodynamics or cystoscopy
• Provision of treatments such as bladder retraining, constipation management, patient education, toileting programs, fluid management, pelvic floor muscle rehab, or dietary management
• Fitting devices - urethral inserts, pessaries, vaginal cones
• Offering rehabilitation services - pelvic floor muscle rehab, tibial nerve stimulation, ExMi technology or electrical stimulation
• Performing such surgeries as InterStim, bladder neck suspension, prolapse repair, sub-urethral sling, TVT, Prolift, or artificial sphincter
• Prescribing drugs for incontinence or offering such treatments as biofeedback, acupuncture, botox, herbs or myofascial release for incontinence

Wellness Partners, LLC was formed in 2001 by a group of healthcare professionals who want to put the "heart" back into healthcare. They hope to empower consumers and form partnerships with them to change the health care system through education, interaction and support. Most importantly, they want the consumer to seek wellness always. Care Seeker, LLC was formed in January 2008 to develop, manage and distribute the SEPHIA™ Database.

Access their web sites at:
www.seekwellness.com
www.sephiaschoice.com
www.ContinenceNurse.net

For more information, contact Josee Archer at 800 840-9301.

See Also:

• Broadridge Financial Solutions Goes Live with Visionary Medical Systems, Inc’s Practice Management and DREAM EHR Solution
• Make Weight Loss Easier
• Common sense advice for why you need a flat stomach
• Buy Celebrex for Inflammation – A User’s Guide
• Best Bodybuilding Supplements

[Via Family Medicine]

Join Impact Systems for Compliance-in-a-Box SOP Edition, an hour long Webinar to discuss the value of deploying this enterprise content management solution developed jointly with EMC.

Montchanin, DE (PRWEB) June 5, 2008 — Join Impact Systems for Compliance-in-a-Box SOP Edition, an hour long Webinar to discuss the value of deploying this enterprise content management solution developed jointly with EMC.

What:
Join Impact Systems for Compliance-in-a-Box SOP Edition, an hour long Webinar to discuss the value of deploying this enterprise content management solution. Working closely with EMC, Impact Systems developed Compliance-in-a-Box SOP Edition to provide an enterprise content management solution to small- and mid-size businesses in regulated industries via a preconfigured, templated approach for an affordable, rapid and scalable solution. Compliance-in-a-Box is also being implemented by larger enterprises who need a deployment solution for a specific department or business unit. Compliance-in-a-Box provides organizations with a working Documentum content enterprise application, up and running in six to eight weeks from Test to Production.

For more information and to register go to:
http://www.impactinfosys.com/detailwebinar.asp?webinarid=32

Who Should Attend:
Anyone who needs to more efficiently manage regulated content (Procedures and Recipes) across the enterprise - including IT, operations, compliance, regulatory, and research & development executives from life sciences, manufacturing, R&D, medical device, and consumer product companies.

Why:
The following will be covered:

• Discussion of why Compliance-in-a-Box was developed
• Solution overview: philosophy, value, specifics on what is included in the offering
• Cases in point: how other organizations have successfully deployed Compliance-in-a-Box
• Demonstration: significantly reduce implementation time with EMC Documentum Compliance Manager preconfigured for Procedures such as SOPs
• Q&A session

When:
Wednesday, June 18, 2008

• 10:00 am - 11:00 am PT/1:00 pm - 2:00 pm ET

Space is limited, register today.

About Impact Systems, Inc.
Founded in 1996, Impact Systems provides deployment and migration services for Enterprise Content Management (ECM) systems. Additionally, the company has developed a proprietary suite of configuration management, content and metadata transfer, and bulk load software tools that provide significant time and cost savings for deployments, migrations and ongoing electronic content needs. Impact Systems specializes in deploying regulatory business solutions such as Compliance-in-a-Box for clients in regulated industries. Impact Systems is a member of the EMC2 Consulting/Select Services Team. For more information, visit Impact Systems at www.impactinfosys.com or call 302-573-6864 x121.

See Also:

• The MommyDocs’ 4 Sun Safety Tips - Physician Moms Help Parents Make Sense of Sun Protection Products
• Human Growth Hormone
• Message to Iowa Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight
• Worldwide Epidemiological Cancer Studies Could Lead to Significant Gains
• Somanetics Corporation to Release Second Quarter 2008 Financial Results and Host Conference Call June 18, 2008

[Via Pharmaceuticals]

Ellen de Brabander, PhD., has been appointed Global Head of Merial Research and Development for Merial Limited, a world leader in research, manufacturing and marketing of animal health pharmaceuticals and vaccines. Dr. de Brabander reports to José Barella, Merial’s Executive Chairman, and is a member of Merial’s executive leadership team.

Duluth, GA (Vocus/PRWEB ) June 5, 2008 — Ellen de Brabander, PhD., has been appointed Global Head of Merial Research and Development for Merial Limited, a world leader in research, manufacturing and marketing of animal health pharmaceuticals and vaccines. Dr. de Brabander reports to José Barella, Merial’s Executive Chairman, and is a member of Merial’s executive leadership team.

Dr. de Brabander joins Merial with a broad background of executive R&D positions at DSM, the Netherlands-based global life sciences and material sciences company, and Intervet, the global animal health company. Her most recent position was Head of R&D for Intervet.

As Global Head of Merial R&D, Dr. de Brabander will lead the company’s global research and new product development activities in nine R&D centers around the world. Merial’s R&D division employs more than 700 people.

“The Animal Health industry is a very attractive environment for research and development,” said Dr. de Brabander. “There is a constant and strong demand for new and better products, but this is also a business with complexity and dynamics that are very different from other industries. It is exciting to be able to meet this market demand by applying new technologies that allow us to develop products that make a real difference for our customers. Merial’s capabilities in these new technological areas are impressive. I am fully committed to further strengthen the innovative power at Merial. I am very pleased to have joined Merial because it is an innovation-driven, world-leading animal health company with a strong existing foundation in all major species,” she said.

During the first part of Dr. de Brabander’s career with DSM, she held successive global senior executive-level positions in the Coating Resins and Chemicals divisions. She was appointed CEO of DSM’s Pharma Chemicals in 2004. The following year, she was named Vice President Corporate Technology for all of DSM.

As Head of R&D and Board Member for Intervet beginning in 2006, Dr. de Brabander was responsible for that company’s global R&D organization, managing the R&D activities in both vaccines and pharmaceuticals at 14 sites.

Dr. de Brabander has a PhD in bio-organic chemistry from Leiden University, and completed a post-doctoral program at the Massachusetts Institute of Technology. She will be relocating to Duluth from the Netherlands later this year.

Dr. de Brabander succeeds Dr. Kevin Schultz, who leaves after performing the role of Head of Merial R&D for ten years. Dr. Schultz will remain with Merial as a consultant on special projects and external collaborations.

About Merial
Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs more than 5,400 people and operates in more than 150 countries worldwide. Its 2007 sales were nearly $2.5 billion. Merial Limited is a joint venture between Merck & Co., Inc. and sanofi-aventis. For more information, please see www.merial.com.

Contacts:
Steve Dickinson
Merial
678-638-3683

Philip Connolly
Merial
+44 1279 77 5846

See Also:

• Interface Biologics Inc. achieves reductions in platelet adhesion similar to heparin coated devices with use of non drug surface additive
• San Diego Dentist Dr. Ernest Wong Now Offers One-Appointment CEREC Porcelain Crowns
• Laser Hair Removal Video Contest Begins; Winner Gets $500 Gift Card
• Martin, Harding and Mazzotti Successfully Run Memorial Day “Safe Ride Home” Program to Lower Drunken Driving Incidents
• Two TV Personalities Just Named Co-Spokespersons For MyGymFloor.Com, Star In Video — Bravo’s Finest Fitness and Lifestyle Expert, Dr. John Spencer Ellis and HGTV’s Dazzling Designer, Kelli Ellis, Join Forces to Promote Benefits of H

[Via Pharmaceuticals]

Visionary Medical Systems, Inc announces the successful installation and implementation of Visionary Office PM® practice management software, and CCHIT certified DREAM EHR at Broadridge's Financial Solution's.

Tampa, FL (PRWEB) June 5, 2008 — Visionary Medical Systems, Inc is pleased to announce the successful installation and implementation of their Visionary Office PM® practice management software, and CCHIT certified DREAM EHR at Broadridge's Financial Solution's Journal Square and Edgewood locations. Thanks to Visionary's Implementation Team and the dedication of Broadridge's Medical and Technical Staff the software was installed, clerical and medical staff were trained and 'Go Live" completed within a remarkable 30 day period. "Thank you all for your great support and dedication to getting this project implemented one week ahead of schedule! Broadridge, ADP, and Visionary team members worked together and communicated in a manner that was nothing short of commendable", stated Jack Russo, Senior Director Global Shared Services.

Broadridge offers in-house medical facilities to their employees. The facility is currently staffed by Drs. Frank and Tanael. Dr. Carter (who is no longer with the group), played an instrumental role in choosing the software they wanted to use to service their employees. Sharon Migdol, RN from the Edgewood Medical Department states, "I must tell you how smoothly I felt this transition was for us. I feel more confident in this short period of time using this system than I thought I would at this point.

About Broadridge
Broadridge is a leading full-service outsourcing provider to the global financial industry, capable of meeting the most demanding requirements for efficient, secure and scalable operational support. Their reach spans the world, and encompasses an extensive array of services - from account opening and securities transaction processing to correspondent clearing to document management and investor communications as well as full operational staff outsourcing. A steadfast source of processing support, their financial services help institutions and public companies increase productivity, streamline operations, enter new markets with new products more quickly, drive down back-office costs and better manage risk.

About Visionary Medical Systems, Inc.
Visionary Medical Systems, Inc http://visionarymed.com is the leading provider of healthcare software solutions. Through Visionary's solutions, including their payer division "USMD", they offer an integrated line of clinical, financial, document management and chronic care management modules designed to automate healthcare processes. With their goal of improving patient care, decreasing physician errors, and increasing practice income, Visionary's unique, affordable solutions connect the patient, provider, and payer. Contact Visionary Medical Systems, Inc at 888-895-2466.

See Also:

• LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
• Fidelity National Financial, Inc. Announces the Sale of Approximately 20 Percent of its Ownership Stake in Sedgwick CMS
• Tri-anim and Bound Tree Medical Merge to Create Nation’s Leading Specialty Health Care Distributor
• Erase Pain in Mere Minutes
• Weight Management Solution Helps You Lose or Gain as Much Weight as You Choose

[Via Family Medicine]

RealDealDocs.com offers various online legal documents from agreements to contracts for your download and printing convenience. This release contains a copy of the NPS Pharmaceuticals Inc distribution and license agreement drafted by law firm Morgan Lewis, honored by Amlaw for their pro bono work.

New York, New York (PRWEB) June 5, 2008 — RealDealDocs.com is in the forefront of online sample legal document resources and has just released the distribution and license agreement for NPS Pharmaceuticals Inc drafted by Amlaw firm Morgan Lewis, recognized for their pro bono work.

A distribution agreement is a legal document governing the sales and marketing of an item of merchandise by a distributor. And a license agreement is a legal document demonstrating the granting of permission by a party ("licensor") to another party ("licensee") as an element of an agreement between those parties. The distribution and license agreement between NPS Pharmaceuticals Inc and Nycomed Corporation was formed for the purpose of Nycomed to develop, promote and market the pharmaceutical products that NPS Pharmaceuticals Inc has the patent, know-how and rights to.

RealDealDocs.com presents a complimentary copy of the NPS Pharmaceuticals Inc distribution and license agreement as a template for professionally drafted legal documents. The law firm of Morgan Lewis is both a well known and Amlaw celebrated law firm that was recognized for their pro bono work by the Amlaw publication. In celebration of this honor, RealDealDocs.com has decided to release this distribution and license agreement free of charge.

Amlaw is both a website and magazine focused on legal businesses and lawyers around the world. It is a respected leader in daily news in the legal industry. Every year this respected publication publishes categorized lists of its picks of the best law firms. This annual Amlaw occurrence is the equivalent to the Academy Awards for lawyers! And RealDealDocs.com is happy to host and provide the work of many of Amlaw's top picks.

All of the documents at RealDealDocs.com are drafted by top US law firms; including documents from Fortune 500 companies and small cap companies alike. From the National Law Journal's top 250 law firms, 40 of them use the RealDealDocs.com technology. And a majority of the law firms honored in the Amlaw review have their work on display and available at RealDealDocs.com.

Lawyers who use RealDealDocs.com, do so in order to lower the amount of time needed to draft a legal agreement. Even business professionals can use RealDealDocs.com in an effort to research a company or see how they handle various legal transactions.

Visitors at RealDealDocs.com can search nearly one million documents and 10 million clauses for free. As a member of RealDealDocs.com you can also edit, save and download these documents in a printer-friendly format for your own use.

RealDealDocs.com provides an enormous variety of contracts and agreements for companies in every industry from banking, clothing and marketable goods to the defense industry. And with over 10 million legal documents and clauses in addition to the NPS Pharmaceuticals Inc distribution and license agreement, RealDealDocs.com has secured itself as an online leader in sample legal documents.

More Links:

• The Cost Of Gastric Banding And What You Should Know
• Instant Herbal Remedy for Insect Bites and Stings
• Yeast Infection And Treating It
• How To Choose Pilates Classes & Firms!
• Everything You Ever Wanted To Know About Acne Treatment

[Via Pharmaceuticals]

Ariadne announced today that Pfizer, Inc. has purchased a multi-site license for Pathway Studio Enterprise software. Pfizer is going to use it to assemble reference networks of biological interactions from internal and public data sources for interpretation of experimental results throughout its research facilities.

Rockville, MD (PRWEB) June 5, 2008 - Ariadne announced today that Pfizer, Inc. has purchased a multi-site license for Pathway Studio Enterprise software. Pfizer is going to use it to assemble reference networks of biological interactions from internal and public data sources for interpretation of experimental results throughout its research facilities.

Pathway Studio Enterprise includes functionality to import and analyze microarray and proteomics data, and includes the Ariadne ResNet database, a collection of interaction data retrieved by MedScan technology from PubMed and open-text journals. Pfizer additionally purchased a copy of Prolexys Human Interaction Database, a proprietary high-confidence source of human protein interactions built by Prolexys, Inc. using Y2H technology and repackaged for Pathway Studio.

"Pathway Studio provides Pfizer researchers with easy access to publicly available scientific information, and a way to integrate our proprietary data along with third party high-confidence data such as the Human Interaction Database from Prolexys. We can also integrate Pathway Studio with in-house tools to assemble targeted data sets for research in specific disease, biomarker, and drug related topics," said Giles Day, Senior Director, Target & Mechanism Informatics at Pfizer.

"The open architecture of Pathway Studio Enterprise is proving to be an advantage for many companies, allowing them to integrate their own databases, experimental data, and custom-made datasets," said Dr. Ilya Mazo, President of Ariadne. "MedScan seems to be the right tool to assemble this data rapidly and maintain concurrency with the emergence of scientific knowledge."

For more information about Pathway Studio Enterprise and MedScan Technology, please contact Ariadne at 240-453-6296 or www.ariadnegenomics.com.

About Ariadne:
ARIADNE (www.ariadnegenomics.com) Pathway Studio software is used worldwide as a comprehensive solution for analysis and searching of pathways and molecular interaction information. Ariadne offers desktop and enterprise editions of Pathway Studio which are supported by several commercial and publicly available molecular interaction databases including ResNet Mammalian and ResNet Plant. Pathway Studio powered by MedScan Technology, which can be used to edit and enhance database content from the current literature and from experimental data. Prolexys Human Interaction Database is property of Prolexys Pharmaceutical, for which Ariadne is the exclusive sales channel.

More Links:

• TotalBeauty.com Tops 100,000 Unique Consumer-Written Beauty Product Reviews
• Instant Herbal Remedy for Insect Bites and Stings
• CR Certification Corporation (”CardioReady”) Launches New Service Targeting Fortune 500 Companies to Help Extend Their Duty of Care to Employees While on the Road
• Nail Fungus – Can Nail Fungus Be Eliminated Permanently?
• Men Speak Up About the Male’s Side of Surrogacy

[Via Pharmaceuticals]